Evidence map›Paper›PMID 22515275›Full record

ArticleAddiction biology2012

The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety.

Jesse R Schank, Andrea L Goldstein, Kelly E Rowe, Courtney E King, Julie A Marusich, Jenny L Wiley, F Ivy Carroll, Annika Thorsell, Markus Heilig

Abstract read
In one paragraph

Article in Addiction biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed.

  1. BLA kappa opioid receptor inputs to the BNST mediate social stress-induced increases in alcohol drinking.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. BLAbioRxiv : the preprint server for biology · 2024
    Article
  7. Article
  8. Article
  9. Review
  10. Evaluation of Specific Binding of [ACS medicinal chemistry letters · 2021
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research.Handbook of experimental pharmacology · 2020
    Review
  18. Dynorphin-kappa opioid receptor activity in the central amygdala modulates binge-like alcohol drinking in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jesse R SchankLaboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA. jesse.schank@nih.gov
Andrea L Goldstein
Kelly E Rowe
Courtney E King
Julie A Marusich
Jenny L Wiley
F Ivy Carroll
Annika Thorsell
Markus Heilig

Funding

Discovery and validation of novel targets for pharmacotherapy of alcoholismZIAAA000487 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI LOVINGER, DAVID M · 2009 to 2015
$23.6M
Selective Opioid Antagonists as Medications for Drug AbuseR01DA009045 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI CARROLL, FRANK IVY · 1994 to 2014
$5.6M
Early Environments and Genetic Effects on Alcohol Abuse and Associated BehaviorZIAAA000214 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI HEILIG, MARKUS · 2009 to 2010
$1.2M
Intramural NIH HHS ZIA AA000214NIDA NIH HHS DA09045NIDA NIH HHS R01 DA009045
6 · The paper itself

Abstract

The role of kappa-opioid receptors (KOR) in the regulation of alcohol-related behaviors is not completely understood. For example, alcohol consumption has been reported to increase following treatment with KOR antagonists in rats, but was decreased in mice with genetic deletion of KOR. Recent studies have further suggested that KOR antagonists may selectively decrease alcohol self-administration in rats following a history of dependence. We assessed the effects of the KOR antagonist JDTic on alcohol self-administration, reinstatement of alcohol seeking induced by alcohol-associated cues or stress, and acute alcohol withdrawal-induced anxiety ('hangover anxiety'). JDTic dose-dependently reversed hangover anxiety when given 48 hours prior to testing, a time interval corresponding to the previously demonstrated anxiolytic efficacy of this drug. In contrast, JDTic decreased alcohol self-administration and cue-induced reinstatement of alcohol seeking when administered 2 hours prior to testing, but not at longer pre-treatment times. For comparison, we determined that the prototypical KOR antagonist nor-binaltorphimine can suppress self-administration of alcohol at 2 hours pre-treatment time, mimicking our observations with JDTic. The effects of JDTic were behaviorally specific, as it had no effect on stress-induced reinstatement of alcohol seeking, self-administration of sucrose, or locomotor activity. Further, we demonstrate that at a 2 hours pre-treatment time JDTic antagonized the antinociceptive effects of the KOR agonist U50,488H but had no effect on morphine-induced behaviors. Our results provide additional evidence for the involvement of KOR in regulation of alcohol-related behaviors and provide support for KOR antagonists, including JDTic, to be evaluated as medications for alcoholism.

Indexed as

AlcoholismAnimalsAnxietyCentral Nervous System DepressantsConditioning, OperantCuesDynorphinsEthanolMaleNarcotic AntagonistsPiperidinesRatsRats, WistarReceptors, Opioid, kappaRecurrenceStress, Psychological7-hydroxy-N-(1-((4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamideCentral Nervous System DepressantsDynorphinsEthanolNarcotic AntagonistsPiperidinesReceptors, Opioid, kappaTetrahydroisoquinolines

Identifiers

PMID22515275
PMCPMC3334348

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.